SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (633)3/26/1999 5:26:00 PM
From: Mark Peterson CPA  Read Replies (1) | Respond to of 942
 
Anthony, here's a later headline post:

FDA PANEL RECOMMENDS WITHDRAWING WARNER LAMBERT'S <WLA.N>

REZULIN AS MONOTHERAPY
MORE
Rtr 17:04 03-26-99

Monday's going to be interesting....

Best regards,

Mark A. Peterson



To: Anthony Wong who wrote (633)3/26/1999 5:29:00 PM
From: margie  Read Replies (2) | Respond to of 942
 
The FDA panel recommended continued use of Rezulin in combination therapy, with tests to monitor liver functions, but the panel recommended withdrawing it for monotherapy. Apparently most use is in combination therapy now.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News